Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.

Abstract excerpt

Pancreatic ductal adenocarcinoma (PDAC) is a malignancy characterized by a poor prognosis and high mortality rate. Genetic mutations and altered molecular pathways serve as targets in precise therapy. Using next-generation sequencing (NGS), these aberrant alterations can be identified and used to develop strategies that will selectively kill cancerous cells in patients with PDAC. The realization of targeted...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antibodies, Bispecific
• Share to Carcinoma, Pancreatic Ductal